1. United States of America Stocks

  2. •

    Financial Services

  3. •

    Shell Companies
Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares

DMAA
Drugs Made In America Acquisition Corp. Ordinary SharesUS flagNASDAQ Global Select
10.70
USD
+0.03
- -
360.77MMarket Cap
Drugs Made In America Acquisition Corp. Ordinary Shares
DMAA
(NASDAQ Global Select)

Recent

price

10.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2024
2025
TTM
FRC
- -
- -
- -
Revenue per Share
- -
0.19
0.2
Basic EPS, GAAP
- -
-0.02
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
Dividend per Share
- -
7.4
6.99
Book Value per Share
- -
7.4
6.99
Tangible Book Value per Share
- -
31
34
Basic Weighted Avg Shares
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Operating Margin (%)
- -
- -
- -
Depreciation Expense
- -
6
7
Net Income, GAAP
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
Profit Margin (%)
-1
- -
- -
Working Capital
- -
- -
- -
LT Debt
- -
233
235
Total Equity
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
2.89
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
ST Debt
- -
- -
LT Borrowings
- -
- -
LT Finance Leases
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
Shares Outstanding
34
34
Market Capitalization
317
352

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Total Current Assets
- -
- -
Cash, Cash Equivalents & STI
- -
- -
Accounts Receivable, Net
- -
- -
Inventories
- -
- -
Total Current Liabilities
- -
- -
Payables & Accruals
- -
- -
ST Debt
- -
- -
Deferred Revenue
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-95,116.31%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
0.05
0.07
0.07
- -
0.19
2026
0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
TCW Special Purpose Acquisition Corp. (TSPQ-WT)
Infinite Networks Corporation (INNX)
BioPlus Acquisition Corp. (BIOS)
Cantor Equity Partners VI, Inc. Class A Ordinary Shares (CEPS)
DPCM Capital, Inc. (XPOA-UN)
Altimar Acquisition Corp. II (ATMR)
Business
Drugs Made In America Acquisition Corp. functions as a special purpose acquisition company, or SPAC, established to pursue a business combination. The company aims to identify and merge with, exchange capital stock, acquire assets from, or reorganize with one or more businesses, specifically targeting the U.S. pharmaceutical industry. Its core strategy is to invest in entities focused on the domestic manufacturing of approved pharmaceuticals, active pharmaceutical ingredients, and related contract development and manufacturing services. The ultimate objective is to bolster American pharmaceutical independence and enhance the resilience of the U.S. medical supply chain by onshoring critical drug production. Incorporated in 2024, the company successfully completed its initial public offering in January 2025, raising $200 million, with its funds held in a trust account while it actively seeks a suitable acquisition target.

Company News

APIChatGPT

  • defenseworld.net

    Drugs Made In America Acquisition Corp. $DMAA Shares Sold by DLD Asset Management LP